InnoCan Pharma Corporation (INNO)
CSE
2.20
-0.05 (-2.22%)
Closed
Aug 25, 2026
Day's Range
2.192.20
52 wk Range
2.0021.00
Financial Statements - INNO - InnoCan Pharma Corporation
Revenue
26.61M▼ 9.6%
Net Income
-341.00K▼ 30.2%Net Margin -1.3%
EBITDA
-1.21M▼ 0.1%
Free Cash Flow
479.00K▲ 130.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 26.61M | 29.43M | - | 2.55M | 196K | 8K |
| Cost of Goods | 2.68M | 3.25M | - | 452K | 75K | 5K |
| Gross Profit | 23.93M | 26.18M | - | 2.10M | 121K | 3K |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -1.25M | -1.24M | - | -6.26M | -7.48M | -4.72M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 1.34M | 2.17M | - | 2.35M | -2.59M | -5.22M |
| Pre Tax Income | 85K | 919K | - | -3.88M | -10.09M | -9.95M |
| Income Tax | 426K | 1.18M | - | 1K | 0 | 0 |
| Net Income | -341K | -262K | - | -3.88M | -10.09M | -9.95M |
| EPS Basic | -0.25 | -0.65 | -0.017 | -0.016 | -0.05 | -0.06 |
| EPS Diluted | -0.25 | -0.65 | -0.017 | -0.016 | -0.05 | -0.06 |
| Basic Shares Outstanding | 4.47M | 4.30M | 180.41M | 171.28M | 154.49M | 111.47M |
| Diluted Shares Outstanding | 4.47M | 4.30M | 180.41M | 171.28M | 154.49M | 111.47M |
| Ebit | 88K | 926K | - | -3.88M | -10.07M | -9.94M |
| Ebitda | -1.21M | -1.21M | - | -6.21M | -7.43M | -4.68M |
| Net Income Continuous Operations | -341K | -262K | - | -3.88M | -10.09M | -9.95M |
| Minority Interests | -783K | -1.57M | - | 125K | 44K | 0 |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
